Cure My Disease

Don't miss your cure!

 Log in / Sign up

Blood clot markers may forecast stroke outcomes

NCT ID NCT05974111

Knowledge-focused Sponsor: Ziekenhuis Oost-Limburg Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 03, 2026 · Last updated Sep 04, 2026 · Updated 1 time

Summary

Researchers are studying blood samples from people who have had a stroke to understand how blood clotting and inflammation affect recovery. They will take samples at several time points during the first week and measure markers of coagulation and inflammation. The goal is to see if these markers can predict who will have a good or poor outcome three months later. This study does not test a new treatment, but it may reveal clues for future therapies.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
blood sampling for coagulation and inflammation profiling
What this could lead to
If successful, this could identify blood markers that help predict recovery after stroke and guide future treatments.
What could go wrong
This is an observational study, so it won't test a new treatment. The markers may not reliably predict outcomes in all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

379 people

The number who actually took part.

Started

May 2023

Finished

Aug 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study population will consist of patients presenting at the hospital with ischaemic stroke, haemorrhagic stroke or aneurysmal subarachnoid haemorrhage. As our hospital is a referral centre, both referred patients and patients presenting at our emergency department will be screened for eligibility.

Ages

18 years and older

Sex

Anyone

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Presenting at the hospital with ischaemic stroke, haemorrhagic stroke, aneurysmal subarachnoid haemorrhage or any other type of non-traumatic, intracranial bleeding In patients with minor ischemic stroke (NIHSS \<= 4) only baseline lab sampling will be performed (T0 and T0B). Exclusion Criteria: * Refusal of participation by patient or legal representative * Traumatic intracranial (subdural, subarachnoid, epidural haematoma) bleeding * Patients receiving treatment with interference on coagulation (pro / anti) before first sampling: in this group of patients the coagulation assessment at presentation will be excluded, further lab sampling is performed according to protocol. * Patients categorized as having stroke mimic will be excluded from analysis afterwards

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Aneurysmal subarachnoid hemorrhage are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acquired aneurysmal subarachnoid hemorrhage hemorrhagic stroke ischemic stroke subarachnoid hemorrhage

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Aneurysmal subarachnoid hemorrhage Haemorrhagic stroke Ischemic stroke

Contacts and locations

Locations

  • Ziekenhuis Oost-Limburg

    Genk, 3600, Belgium

More trials for these conditions

Other studies related to the condition(s) this trial covers.